Syndax Pharmaceuticals, Inc. Earnings Per Share, Basic and Diluted
Syndax Pharmaceuticals, Inc. (SNDX) reported Earnings Per Share, Basic and Diluted of -$0.63 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-09
- Syndax Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.63.
- Syndax Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.40.
- Syndax Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.44.
- Syndax Pharmaceuticals, Inc. earnings per share, basic and diluted for the quarter ending 2021-03-31 was -$0.54.
- Syndax Pharmaceuticals, Inc. earnings per share, basic and diluted for fiscal 2020 was -$1.87.
- Syndax Pharmaceuticals, Inc. earnings per share, basic and diluted for fiscal 2019 was -$1.84.
- Syndax Pharmaceuticals, Inc. earnings per share, basic and diluted for fiscal 2018 was -$2.92.
- Syndax Pharmaceuticals, Inc. earnings per share, basic and diluted for fiscal 2017 was -$2.90.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | -$0.63 10-Q · filed 2022-05-09 | ||||
| 2021-09-30 | -$0.40 10-Q · filed 2021-11-15 | -$0.84 derived: net income ÷ weighted average shares · filed 2022-11-03 | -$1.38 10-Q · filed 2021-11-15 | -$1.82 derived: net income ÷ weighted average shares · filed 2022-11-03 | |
| 2021-06-30 | -$0.44 10-Q · filed 2021-08-09 | -$0.98 10-Q · filed 2021-08-09 | -$1.43 derived: net income ÷ weighted average shares · filed 2022-08-08 | -$1.89 derived: net income ÷ weighted average shares · filed 2022-08-08 | |
| 2021-03-31 | -$0.54 10-Q · filed 2022-05-09 | -$0.99 derived: net income ÷ weighted average shares · filed 2022-05-09 | -$1.45 derived: net income ÷ weighted average shares · filed 2022-05-09 | -$1.88 derived: net income ÷ weighted average shares · filed 2022-05-09 | |
| 2020-12-31 | -$0.44 10-K · filed 2021-03-12 | -$0.91 derived: net income ÷ weighted average shares · filed 2021-11-15 | -$1.33 derived: net income ÷ weighted average shares · filed 2021-11-15 | -$1.87 10-K · filed 2021-03-12 | |
| 2020-09-30 | -$0.46 10-Q · filed 2021-11-15 | -$0.88 derived: net income ÷ weighted average shares · filed 2021-11-15 | -$1.43 10-Q · filed 2021-11-15 | -$1.87 derived: net income ÷ weighted average shares · filed 2022-03-01 | |
| 2020-06-30 | -$0.42 10-Q · filed 2021-08-09 | -$0.97 10-Q · filed 2021-08-09 | -$1.41 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$1.82 derived: net income ÷ weighted average shares · filed 2022-03-01 | |
| 2020-03-31 | -$0.56 10-Q · filed 2021-05-11 | -$1.00 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$1.41 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$1.88 derived: net income ÷ weighted average shares · filed 2022-03-01 | |
| 2019-12-31 | -$0.44 10-K · filed 2021-03-12 | -$0.85 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$1.32 derived: net income ÷ weighted average shares · filed 2022-03-01 | -$1.84 10-K · filed 2021-03-12 | |
| 2019-09-30 | -$0.41 10-K · filed 2021-03-12 | -$0.88 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$1.40 10-Q · filed 2020-11-05 | -$2.08 derived: net income ÷ weighted average shares · filed 2021-03-12 | |
| 2019-06-30 | -$0.47 10-K · filed 2021-03-12 | -$1.00 10-Q · filed 2020-08-06 | -$1.69 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$2.36 derived: net income ÷ weighted average shares · filed 2021-03-12 | |
| 2019-03-31 | -$0.53 10-K · filed 2021-03-12 | -$1.23 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$1.91 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$2.65 derived: net income ÷ weighted average shares · filed 2021-03-12 | |
| 2018-12-31 | $0.70 10-K · filed 2020-03-05 | -$0.70 10-K · filed 2019-03-07 | -$1.38 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$2.13 derived: net income ÷ weighted average shares · filed 2021-03-12 | -$2.92 10-K · filed 2021-03-12 |
| 2018-09-30 | $0.68 10-K · filed 2020-03-05 | -$0.68 10-Q · filed 2018-11-05 | -$1.42 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$2.21 10-Q · filed 2019-11-07 | -$3.01 derived: net income ÷ weighted average shares · filed 2020-03-05 |
| 2018-06-30 | $0.74 10-K · filed 2020-03-05 | -$0.74 10-Q · filed 2018-08-08 | -$1.54 10-Q · filed 2019-08-07 | -$2.33 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$3.02 derived: net income ÷ weighted average shares · filed 2020-03-05 |
| 2018-03-31 | $0.79 10-K · filed 2020-03-05 | -$0.79 10-Q · filed 2018-05-09 | -$1.59 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$2.28 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$2.98 derived: net income ÷ weighted average shares · filed 2020-03-05 |
| 2017-12-31 | -$0.80 10-K · filed 2019-03-07 | -$1.48 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$2.18 derived: net income ÷ weighted average shares · filed 2020-03-05 | -$2.90 10-K · filed 2020-03-05 | |
| 2017-09-30 | -$0.84 10-K · filed 2019-03-07 | -$0.68 10-Q · filed 2017-11-08 | -$1.38 derived: net income ÷ weighted average shares · filed 2019-03-07 | -$2.08 10-Q · filed 2018-11-05 | -$2.69 derived: net income ÷ weighted average shares · filed 2019-03-07 |
| 2017-06-30 | -$0.47 10-K · filed 2019-03-07 | -$0.70 10-Q · filed 2017-08-10 | -$1.41 10-Q · filed 2018-08-08 | -$2.01 derived: net income ÷ weighted average shares · filed 2019-03-07 | -$2.84 derived: net income ÷ weighted average shares · filed 2019-03-07 |
| 2017-03-31 | -$2.85 10-K · filed 2019-03-07 | -$0.71 10-Q · filed 2017-05-09 | -$1.31 derived: net income ÷ weighted average shares · filed 2019-03-07 | -$2.14 derived: net income ÷ weighted average shares · filed 2019-03-07 | -$2.61 derived: net income ÷ weighted average shares · filed 2019-03-07 |
| 2016-12-31 | -$0.59 10-K · filed 2018-03-08 | -$1.43 derived: net income ÷ weighted average shares · filed 2019-03-07 | -$1.90 derived: net income ÷ weighted average shares · filed 2019-03-07 | -$3.22 10-K · filed 2019-03-07 | |
| 2016-09-30 | -$0.84 10-K · filed 2018-03-08 | -$1.31 derived: net income ÷ weighted average shares · filed 2018-03-08 | -$2.70 10-Q · filed 2017-11-08 | -$4.47 derived: net income ÷ weighted average shares · filed 2018-03-08 | |
| 2016-06-30 | -$0.47 10-K · filed 2018-03-08 | -$1.91 10-Q · filed 2017-08-10 | -$4.03 derived: net income ÷ weighted average shares · filed 2018-03-08 | -$15.44 derived: net income ÷ weighted average shares · filed 2018-03-08 | |
| 2016-03-31 | -$2.85 10-K · filed 2018-03-08 | -$9.39 derived: net income ÷ weighted average shares · filed 2018-03-08 | -$50.06 derived: net income ÷ weighted average shares · filed 2018-03-08 | -$88.06 derived: net income ÷ weighted average shares · filed 2018-03-08 | |
| 2015-12-31 | -$105.57 10-K · filed 2017-03-14 | -$845.44 derived: net income ÷ weighted average shares · filed 2018-03-08 | -$1283.04 derived: net income ÷ weighted average shares · filed 2018-03-08 | -$1519.27 10-K · filed 2018-03-08 | |
| 2015-09-30 | -$790.85 10-K · filed 2017-03-14 | -$1262.97 derived: net income ÷ weighted average shares · filed 2017-03-14 | -$1500.34 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | -$440.52 10-K · filed 2017-03-14 | -$649.30 10-Q · filed 2016-08-15 | |||
| 2015-03-31 | -$206.30 10-K · filed 2017-03-14 | ||||
| 2014-12-31 | -$453.02 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |